A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease

Summary

The main aim of this study is to learn about the effect of treatment with vedolizumab IV (vedolizumab) together with adalimumab or vedolizumab (VDZ) together with ustekinumab (UST) in adults with moderate to severe Crohn's Disease, and the effect of treatment with vedolizumab alone, after the dual targeted treatment. The study is conducted in two parts. In Part A, participants will receive the dual targeted treatment (vedolizumab together with either adalimumab or ustekinumab). In part B, participants will receive vedolizumab only.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Crohn's Disease

Eligibility basics and study details

Study type

Interventional

Phase

Phase 4

Ages

18 to 70 years

Sex

All

Healthy volunteers

Not accepted

Sponsor

Takeda

Last updated on ClinicalTrials.gov

September 9, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites